AU2014264445B2 - Treatment of cancer with naltrexone - Google Patents

Treatment of cancer with naltrexone Download PDF

Info

Publication number
AU2014264445B2
AU2014264445B2 AU2014264445A AU2014264445A AU2014264445B2 AU 2014264445 B2 AU2014264445 B2 AU 2014264445B2 AU 2014264445 A AU2014264445 A AU 2014264445A AU 2014264445 A AU2014264445 A AU 2014264445A AU 2014264445 B2 AU2014264445 B2 AU 2014264445B2
Authority
AU
Australia
Prior art keywords
tlr9
subject
naltrexone
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014264445A
Other languages
English (en)
Other versions
AU2014264445A1 (en
Inventor
Rachel Allen
Angus Dalgleish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LDN Pharma Ltd
Original Assignee
LDN Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LDN Pharma Ltd filed Critical LDN Pharma Ltd
Publication of AU2014264445A1 publication Critical patent/AU2014264445A1/en
Application granted granted Critical
Publication of AU2014264445B2 publication Critical patent/AU2014264445B2/en
Assigned to LDN Pharma Limited reassignment LDN Pharma Limited Request for Assignment Assignors: CANCER VACCINE INSTITUTE
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014264445A 2013-05-10 2014-05-12 Treatment of cancer with naltrexone Active AU2014264445B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201308440A GB201308440D0 (en) 2013-05-10 2013-05-10 Therapeutic
GB1308440.5 2013-05-10
PCT/GB2014/051439 WO2014181131A1 (en) 2013-05-10 2014-05-12 Treatment of cancer with naltrexone

Publications (2)

Publication Number Publication Date
AU2014264445A1 AU2014264445A1 (en) 2016-01-07
AU2014264445B2 true AU2014264445B2 (en) 2019-08-15

Family

ID=48672126

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014264445A Active AU2014264445B2 (en) 2013-05-10 2014-05-12 Treatment of cancer with naltrexone

Country Status (13)

Country Link
US (4) US9895438B2 (OSRAM)
EP (1) EP2994137B1 (OSRAM)
JP (1) JP6346269B2 (OSRAM)
KR (1) KR102162038B1 (OSRAM)
CN (1) CN105451740B (OSRAM)
AU (1) AU2014264445B2 (OSRAM)
BR (1) BR112015028269A2 (OSRAM)
CA (1) CA2912203C (OSRAM)
GB (1) GB201308440D0 (OSRAM)
IL (1) IL242533B (OSRAM)
MX (1) MX2015015582A (OSRAM)
RU (1) RU2686325C2 (OSRAM)
WO (1) WO2014181131A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410216D0 (en) 2014-06-09 2014-07-23 Cancer Vaccine Inst Therapeutic
KR20200072445A (ko) * 2017-03-28 2020-06-22 엘디엔 파마 리미티드 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제
GB201704911D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
WO2019055597A1 (en) * 2017-09-13 2019-03-21 National Tuberous Sclerosis Association, Inc. Methods and compositions for the treatment of tsc
WO2020089531A1 (en) * 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
EP3934648A1 (en) 2019-03-06 2022-01-12 LDN Pharma Limited Method of monitoring treatment
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
EP4281046B1 (en) * 2021-01-25 2025-09-10 LDN Pharma Limited Naltrexone compositions
CN114836529B (zh) * 2022-03-30 2023-05-30 唐颢 Ogfr基因或其编码的蛋白在心肌损伤辅助诊断及治疗中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288074B1 (en) * 1998-11-17 2001-09-11 Bernard Bihari Method of treating lymphoproliferative syndrome
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20090169508A1 (en) * 2003-05-16 2009-07-02 Jenkin Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20110136845A1 (en) * 2009-07-16 2011-06-09 Mallinckrodt Inc. (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689332A (en) * 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US6136780A (en) * 1996-03-29 2000-10-24 The Penn State Research Foundation Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
JP5438250B2 (ja) * 2002-05-17 2014-03-12 ジェンケン バイオサイエンスィズ，インコーポレイテッド オピオイド及びオピオイド様の化合物並びにそれらの使用
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
EP2012772A1 (en) * 2006-04-26 2009-01-14 The Uab Research Foundation Reducing cancer cell invasion using an inhibitor of toll like receptor signaling
TR201809739T4 (tr) * 2009-07-16 2018-07-23 Mallinckrodt Llc Toll benzeri reseptör 9 antagonistleri olarak (+)-morfinanlar ve bunların terapötik amaçlı kullanımları.
GB201410216D0 (en) * 2014-06-09 2014-07-23 Cancer Vaccine Inst Therapeutic
GB201704909D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288074B1 (en) * 1998-11-17 2001-09-11 Bernard Bihari Method of treating lymphoproliferative syndrome
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20090169508A1 (en) * 2003-05-16 2009-07-02 Jenkin Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20110136845A1 (en) * 2009-07-16 2011-06-09 Mallinckrodt Inc. (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof

Also Published As

Publication number Publication date
US20220040295A1 (en) 2022-02-10
NZ714999A (en) 2021-05-28
AU2014264445A1 (en) 2016-01-07
WO2014181131A1 (en) 2014-11-13
JP6346269B2 (ja) 2018-06-20
BR112015028269A2 (pt) 2017-07-25
KR20160032013A (ko) 2016-03-23
MX2015015582A (es) 2016-08-11
EP2994137B1 (en) 2022-12-14
CN105451740B (zh) 2019-07-19
US20180207263A1 (en) 2018-07-26
CA2912203A1 (en) 2014-11-13
RU2015152785A (ru) 2017-06-16
JP2016524602A (ja) 2016-08-18
US20230390388A1 (en) 2023-12-07
CA2912203C (en) 2021-08-17
KR102162038B1 (ko) 2020-10-06
RU2686325C2 (ru) 2019-04-25
EP2994137A1 (en) 2016-03-16
GB201308440D0 (en) 2013-06-19
CN105451740A (zh) 2016-03-30
US20160106832A1 (en) 2016-04-21
US9895438B2 (en) 2018-02-20
IL242533B (en) 2020-10-29

Similar Documents

Publication Publication Date Title
US20230390388A1 (en) Treatment of Cancer with Naltrexone
Martinez et al. The role of chloroquine and hydroxychloroquine in immune regulation and diseases
Dongye et al. Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity
Siveen et al. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model
US12144807B2 (en) Priming of cancer cells with low dose naltrexone
Cho et al. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma
Yu et al. Macrophage‐associated osteoactivin/GPNMB mediates mesenchymal stem cell survival, proliferation, and migration via a CD44‐dependent mechanism
Camargo et al. Intravesical immunomodulatory imiquimod enhances bacillus Calmette-Guérin downregulation of nonmuscle-invasive bladder cancer
Zhu et al. β‐Glucan produced by lentinus edodes suppresses breast cancer progression via the inhibition of macrophage M2 polarization by integrating autophagy and inflammatory signals
WO2020081971A1 (en) Combinations for immune-modulation in cancer treatment
US10149846B2 (en) Antitumor agent
Li et al. Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer
NZ714999B2 (en) Treatment of cancer with naltrexone
AU2015400687A1 (en) Method for inducing early T memory response with short peptides anti-tumor vaccine
Di Grazia et al. Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells.
Nazimek et al. Macrophage function in allergic and autoimmune responses
JP2019151621A (ja) Ｋａｔ阻害活性を有する化合物を含有するがん治療用組成物
Michiue et al. DDIS-20. NEW A6K BORON DRUG DELIVERY SYSTEM FOR CLINICAL APPLICATION OF BORON NEUTRON CAPTURE THERAPY (BNCT)
Guo et al. Phase I clinical study of a multi-kinase inhibitor TG02 capsule for the treatment of recurrent high-grade gliomas with failed temozolomide treatment in Chinese patients
KR20140102811A (ko) 이미퀴모드를 포함하는 항암 치료 보조용 약학 조성물
CN119656163A (zh) 一种用于诱导肿瘤内三级淋巴结构和增强免疫检查点阻断的基于水凝胶的递送系统及其方法
Jungwirth et al. DDIS-21. KIF11 INHIBITORS FILANESIB AND ISPINESIB AS NOVEL AGENTS FOR MENINGIOMA THERAPY
RU2021122146A (ru) L718 и/или l792 мутантный ингибитор egfr, резистентный к лечению
TW201909894A (zh) 包含血管破壞劑及免疫查核點抑制劑之用於預防或治療癌症的組合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LDN PHARMA LIMITED

Free format text: FORMER OWNER(S): CANCER VACCINE INSTITUTE